Scarica l'app Stockscreener
11.01
1.70%
-0.19
Dopo l'orario di chiusura:
11.01
Trevi Therapeutics Inc Borsa (TRVI) Ultime notizie
Why Trevi Therapeutics (TRVI) Is Down 17.2% After Doubling Down On Parallel IPF Cough TrialsAnd What's Next - simplywall.st
Trevi Therapeutics, Inc. $TRVI Stock Position Increased by Pivotal bioVenture Partners Investment Advisor LLC - MarketBeat
Rosalind Advisors Inc. Trims Stake in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics chief Farrell Simon to address pre launch excellence at U.S. rare disease event - Traders Union
Trevi Therapeutics at Leerink Global: Strategic Cough Treatment Advances By Investing.com - Investing.com Canada
Trevi Therapeutics: Navigating The 'Catch-22' Of Opioid-Based Cough Control (NASDAQ:TRVI) - Seeking Alpha
Zacks.com featured highlights include Trevi, Metalla Royalty & Streaming and Vermilion - The Globe and Mail
Zacks.com spotlighted features include Trevi, Metalla Royalty & Streaming, and Vermilion - Bitget
Q4 and year end 2025 earnings call announced, Trevi Therapeutics outlines - Traders Union
Trevi Therapeutics to detail 2025 results and business updates Mar. 17 - Stock Titan
Trevi Therapeutics (TRVI) to Release Quarterly Earnings on Tuesday - MarketBeat
Oppenheimer Maintains Outperform on TRVI (March 09, 2026) - Meyka
Trevi Therapeutics (TRVI) Secures FDA Support for Advanced Clini - GuruFocus
Trevi Therapeutics Aligns With FDA on Phase 3 Cough Trials - TipRanks
Up Over 50%: 3 Stocks on the Verge of a Massive Breakout in March - The Globe and Mail
Trevi Therapeutics (NASDAQ:TRVI) Receives Buy Rating from D. Boral Capital - MarketBeat
TRVI: D. Boral Capital Maintains Buy Rating with $19 Target | TR - GuruFocus
Trevi Therapeutics stock gets Oppenheimer nod on Phase 3 plans By Investing.com - Investing.com Canada
Trevi Therapeutics (NASDAQ:TRVI) Shares Down 9.9%Here's What Happened - MarketBeat
Trevi Therapeutics (TRVI) Advances with Phase 3 Trials for Haduv - GuruFocus
HC Wainwright Reiterates Buy Rating for Trevi Therapeutics (TRVI) at $21 | TRVI Stock News - GuruFocus
Trevi Therapeutics' (TRVI) Buy Rating Reiterated at HC Wainwright - MarketBeat
TRVI Stock Slips After Company Plans Parallel Trials In Lung Disease — Stifel Dismisses Timeline Concerns - Stocktwits
Trevi Therapeutics (TRVI) has successfully completed the End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). - Bitget
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough - Bitget
Trevi Therapeutics Announces Completion of End-of-Phase 2 - GlobeNewswire
How supply chain issues affect Trevi Therapeutics Inc. stock2025 Year in Review & Technical Pattern Based Signals - Naître et grandir
Stock Recap: Can Trevi Therapeutics Inc continue delivering strong returnsWeekly Investment Report & Stepwise Trade Signal Implementation - baoquankhu1.vn
Earnings Recap: Is Trevi Therapeutics Inc stock technically oversoldQuarterly Profit Report & Accurate Buy Signal Alerts - baoquankhu1.vn
Inflation Data: Can Trevi Therapeutics Inc continue delivering strong returnsPortfolio Performance Report & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Can Trevi Therapeutics Inc continue delivering strong returnsQuarterly Profit Report & Safe Entry Trade Reports - baoquankhu1.vn
Value Recap: Can Trevi Therapeutics Inc continue delivering strong returnsJuly 2025 Chart Watch & Advanced Technical Signal Analysis - baoquankhu1.vn
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Trevi Therapeutics, Inc. Senior Management to Present at 2026 Healthcare Conferences - Quiver Quantitative
Chronic cough treatment talks: Trevi execs head to Miami and Philly in March - Stock Titan
MAI Capital Management Cuts Stock Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Assessing Trevi Therapeutics (TRVI) Valuation After Strong Long Term Returns And A Rich Price To Book Ratio - Yahoo Finance
TRVI Should I Buy - Intellectia AI
TRVI PE Ratio & Valuation, Is TRVI Overvalued - Intellectia AI
Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Promising 87% Potential Upside Captures Investor Attention - DirectorsTalk Interviews
TRVI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Does Trevi Therapeutics (TRVI) Have the Potential to Rally 102.07% as Wall Street Analysts Expect? - Finviz
[Form 4] Trevi Therapeutics, Inc. Insider Trading Activity - Stock Titan
Trevi Therapeutics (TRVI) officer receives 35,000-share stock option grant - Stock Titan
Executive at Trevi (NASDAQ: TRVI) granted 160,000 stock options - Stock Titan
Trevi Therapeutics (TRVI) CSO awarded stock options on 85,000 shares - Stock Titan
Will Trevi Therapeutics Inc. outperform its industry peersJuly 2025 Volume & AI Driven Stock Price Forecasts - mfd.ru
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget
Trevi Therapeutics Executives to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference - Quiver Quantitative
Trevi Therapeutics, Inc. (TRVI) Stock Analysis: A Promising 99% Potential Upside In Biotech - DirectorsTalk Interviews
Can Trevi Therapeutics Inc. disrupt its industryDay Trade & Safe Investment Capital Preservation Plans - mfd.ru
Is Trevi Therapeutics Inc. stock resilient to inflationGold Moves & Fast Entry High Yield Stock Tips - mfd.ru
New Haven biotech Trevi Therapeutics builds billion-dollar valuation around lone late-stage cough drug - Hartford Business Journal
Fed Watch: Can Trevi Therapeutics Inc continue delivering strong returns2025 Market Trends & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Analysts Conflicted on These Healthcare Names: Encompass Health (EHC), Hims & Hers Health (HIMS) and Trevi Therapeutics (TRVI) - The Globe and Mail
Aug Outlook: How does Trevi Therapeutics Inc compare to its peersQuarterly Earnings Summary & AI Driven Price Predictions - baoquankhu1.vn
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Brokerages - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of “Buy” by Brokerages - Defense World
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know - MSN
Tejara Capital Ltd Trims Stock Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):